Disc Medicine, Inc. (IRON)
NASDAQ$51.02
Market Cap
$1.76B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
38 of 924
Rank in Industry
28 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
IRON Insider Trading Activity
IRON Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $14,000,076 | 3 | 9 |
Sells | $41,066,125 | 31 | 91 |
Related Transactions
| Bitterman Kevin | director | 1 | $8M | 0 | $0 | $8M |
| Ashiya Mona | director | 1 | $3M | 3 | $16.97M | $-13.97M |
| ORBIMED ADVISORS LLC | director | 1 | $3M | 3 | $16.97M | $-13.97M |
| Yu Jonathan Yen-Wen | Chief Operating Officer | 0 | $0 | 1 | $87,874 | $-87,874 |
| Franchi Jean M. | Chief Financial Officer | 0 | $0 | 1 | $171,163 | $-171,163 |
| Stephenson Pamela | Chief Commercial Officer | 0 | $0 | 1 | $171,217 | $-171,217 |
| White William Richard | director | 0 | $0 | 10 | $837,241 | $-837,241 |
| Khara Rahul | Chief Legal Officer | 0 | $0 | 3 | $950,599 | $-950,599 |
| Savage William Jacob | Chief Medical Officer | 0 | $0 | 5 | $1.71M | $-1.71M |
| Quisel John D | Chief Executive Officer | 0 | $0 | 4 | $3.21M | $-3.21M |
About Disc Medicine, Inc.
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Insider Activity of Disc Medicine, Inc.
Over the last 12 months, insiders at Disc Medicine, Inc. have bought $14M and sold $41.07M worth of Disc Medicine, Inc. stock.
On average, over the past 5 years, insiders at Disc Medicine, Inc. have bought $12M and sold $46.9M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bitterman Kevin (director) — $8M. Ashiya Mona (director) — $3M. ORBIMED ADVISORS LLC (director) — $3M.
The last purchase of 222,223 shares for transaction amount of $8M was made by Bitterman Kevin (director) on 2024‑06‑17.
List of Insider Buy and Sell Transactions, Disc Medicine, Inc.
| 2025-03-12 | Sale | ORBIMED ADVISORS LLC | director | 83,182 0.243% | $54.45 | $4.53M | -4.07% | |
| 2025-03-12 | Sale | Ashiya Mona | director | 83,182 0.243% | $54.45 | $4.53M | -4.07% | |
| 2025-03-11 | Sale | ORBIMED ADVISORS LLC | director | 27,056 0.0784% | $54.01 | $1.46M | -2.58% | |
| 2025-03-11 | Sale | Ashiya Mona | director | 27,056 0.0784% | $54.01 | $1.46M | -2.58% | |
| 2025-03-10 | Sale | ORBIMED ADVISORS LLC | director | 202,146 0.5949% | $54.29 | $10.97M | -0.50% | |
| 2025-03-10 | Sale | Ashiya Mona | director | 202,146 0.5949% | $54.29 | $10.97M | -0.50% | |
| 2025-02-18 | Sale | Quisel John D | Chief Executive Officer | 5,574 0.0164% | $54.58 | $304,229 | -0.96% | |
| 2025-02-18 | Sale | Franchi Jean M. | Chief Financial Officer | 3,136 0.0092% | $54.58 | $171,163 | -0.96% | |
| 2025-02-18 | Sale | Stephenson Pamela | Chief Commercial Officer | 3,137 0.0092% | $54.58 | $171,217 | -0.96% | |
| 2025-02-18 | Sale | Savage William Jacob | Chief Medical Officer | 1,638 0.0048% | $54.58 | $89,402 | -0.96% | |
| 2025-02-18 | Sale | Yu Jonathan Yen-Wen | Chief Operating Officer | 1,610 0.0047% | $54.58 | $87,874 | -0.96% | |
| 2025-02-18 | Sale | Khara Rahul | Chief Legal Officer | 1,161 0.0034% | $54.58 | $63,367 | -0.96% | |
| 2025-02-03 | Sale | Khara Rahul | Chief Legal Officer | 7,500 0.0218% | $55.54 | $416,574 | -0.99% | |
| 2025-01-02 | Sale | Khara Rahul | Chief Legal Officer | 7,500 0.0257% | $62.75 | $470,658 | -11.27% | |
| 2024-12-30 | Sale | Quisel John D | Chief Executive Officer | 13,012 0.0422% | $61.95 | $806,058 | -9.83% | |
| 2024-12-23 | Sale | Quisel John D | Chief Executive Officer | 19,820 0.0661% | $63.14 | $1.25M | -12.66% | |
| 2024-12-16 | Sale | Quisel John D | Chief Executive Officer | 12,791 0.0431% | $66.01 | $844,314 | -15.44% | |
| 2024-12-02 | Sale | White William Richard | director | 1,957 0.0066% | $64.63 | $126,490 | -11.26% | |
| 2024-11-25 | Sale | Savage William Jacob | Chief Medical Officer | 14,183 0.0492% | $65.45 | $928,326 | -10.34% | |
| 2024-11-15 | Sale | Savage William Jacob | Chief Medical Officer | 9,158 0.0289% | $59.64 | $546,153 | -1.61% |
Total: 44
*Gray background shows transactions not older than one year
Insider Historical Profitability
100.92%
| Bitterman Kevin | director | 420549 1.2165% | $21.46M | 1 | 2 | |
| ORBIMED ADVISORS LLC | director | 194209 0.5618% | $9.91M | 1 | 3 | |
| Ashiya Mona | director | 194209 0.5618% | $9.91M | 1 | 3 | |
| AI DMI LLC | 10 percent owner | 3141759 9.0884% | $160.29M | 1 | 0 | +100.92% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.04B | |
$831,902,292 | 108 | 9.34% | $1.58B | |
$20,297,544 | 73 | 103.06% | $1.61B | |
$11,583,737 | 45 | 49.75% | $1.75B | |
$224,267,561 | 40 | 26.78% | $2.17B |
IRON Institutional Investors: Active Positions
| Increased Positions | 88 | +61.11% | 4M | +14.59% |
| Decreased Positions | 61 | -42.36% | 5M | -17.3% |
| New Positions | 37 | New | 734,506 | New |
| Sold Out Positions | 17 | Sold Out | 756,433 | Sold Out |
| Total Postitions | 171 | +18.75% | 27M | -2.72% |
IRON Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Atlas Venture Life Science Advisors, Llc | $140,981.00 | 7.17% | 2.51M | 0 | 0% | 2024-12-31 |
| Fmr Llc | $104,846.00 | 5.33% | 1.87M | +1M | +358.75% | 2024-12-31 |
| Blackrock, Inc. | $104,480.00 | 5.31% | 1.86M | +8,579 | +0.46% | 2024-12-31 |
| Orbimed Advisors Llc | $100,313.00 | 5.1% | 1.79M | 0 | 0% | 2024-12-31 |
| Frazier Life Sciences Management, L.P. | $98,587.00 | 5.01% | 1.75M | 0 | 0% | 2024-12-31 |
| Paradigm Biocapital Advisors Lp | $84,142.00 | 4.28% | 1.5M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $78,394.00 | 3.99% | 1.4M | -444,821 | -24.17% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $78,351.00 | 3.99% | 1.39M | +262,690 | +23.21% | 2024-12-31 |
| Janus Henderson Group Plc | $68,417.00 | 3.48% | 1.22M | +467,988 | +62.41% | 2024-12-31 |
| Vanguard Group Inc | $60,014.00 | 3.05% | 1.07M | +18,716 | +1.78% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.